Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Cemiplimab Phase 3 Trial Stopped Early Due to OS Benefit in Advanced Cervical Cancer

March 15th 2021

A phase 3 trial evaluating single-agent cemiplimab will be stopped early due to positive results demonstrating an overall survival benefit over chemotherapy in patients with recurrent or metastatic cervical cancer who previously received chemotherapy.

FDA Grants Priority Review to Pafolacianine Sodium Injection in Ovarian Cancer

March 3rd 2021

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.

Dostarlimab Gets Positive EU Opinion in Recurrent or Advanced MSI-H Endometrial Cancer

February 26th 2021

February 26, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion to dostarlimab as a treatment for patients with recurrent or advanced microsatellite instability–high/mismatch repair deficient endometrial cancer who have progressed on or following platinum-based chemotherapy.

Dr. Wenham on Rationale for Novel Immunotherapy Combos in Ovarian Cancer

February 24th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue

February 24th 2021

February 24, 2021 - An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

FDA Grants Fast Track Status to Immunotherapy GEN-1 in Advanced Ovarian Cancer

February 22nd 2021

February 22, 2021 - The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

Germline Genetic Testing Gap Persists in Ovarian Cancer, More Delimited Panel Composition Needed to Improve Utility

February 16th 2021

February 16, 2021 - Only 34.3% of 14,689 patients with ovarian cancer received germline genetic testing between 2013 and 2019, revealing persistent underuse of testing among this population.

Coleman Looks Forward to a Big Year for New Cervical Cancer Therapies

February 15th 2021

Robert L. Coleman, MD, discusses key data for these therapies and touched on emerging developments concerning new therapies in ovarian and endometrial cancers.

FDA Approval Sought for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

February 11th 2021

February 10, 2021 - A biologics license application has been submitted to the FDA for the accelerated approval of the antibody-drug conjugate tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.

Promising Novel Targets for Endometrial Cancer Management

February 4th 2021

Novel Strategies in Development for EC Management

February 4th 2021

Therapy Sequencing Through Multiple Lines of Therapy in EC

February 4th 2021

Impact of Pembrolizumab/Lenvatinib Approval in EC

February 4th 2021

Safety/Efficacy Results From EC Cohort of KEYNOTE-146

February 4th 2021

Rationale for Combination Therapy in Advanced EC

February 4th 2021

GARNET Clinical Trial Regimen in Advanced Disease

February 4th 2021

Second-Line Checkpoint Inhibitor for MSI-H Disease

February 4th 2021

Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

February 4th 2021

Treatment Challenges: Advanced Endometrial Cancer

February 4th 2021

Genomic Assessments for Metastatic Disease

January 29th 2021